ShareThis Page
Advisers ask FDA to promote opioid antidote alongside painkillers |

Advisers ask FDA to promote opioid antidote alongside painkillers

The Washington Post
| Tuesday, December 18, 2018 10:39 p.m
The Washington Post
Naloxone is an antidote for opiate overdoses.

Advisers to the Food and Drug Administration recommended Tuesday that labels on prescription opioids urge doctors to simultaneously prescribe the overdose antidote naloxone for at least some of their patients.

Several members of two advisory committees, which met jointly, described their 12-to-11 vote as a message to the government that the fast-acting antidote must be made more widely available, at lower cost and with fewer barriers to obtaining it.

The FDA is not required to follow the recommendations, but the expert panels are influential in crafting policy.

Naloxone, which can be injected or sprayed into the noses of overdose victims, has been available for decades has and saved countless lives during the opioid epidemic. But it still is provided mostly by first responders and harm-reduction groups that distribute it to users of illicit drug; some cities and states have issued “standing orders” for prescriptions for anyone who wants to purchase it at a drugstore.

In April, Surgeon General Jerome Adams issued an unusual advisory urging American opioid users, their families and friends to keep naloxone nearby.

Martin Garcia-Bunuel, a committee member and official with the Veterans Affairs Maryland Health Care System in Baltimore, said he voted for the recommendation in hope of prompting discussion between doctors and patients about keeping naloxone in the home, alongside opioids.

“If done properly,” he said, “it will help create a conversation, standardize a conversation that protects patients who aren’t getting this conversation.”

But other committee members said it makes little sense to recommend a naloxone prescription for everyone who uses the painkillers, since most overdose deaths occur among users of illicit narcotics. Some suggested the recommendation be targeted at high-risk groups, such as people with respiratory problems or histories of abusing prescription narcotics. Others worried that the guidance could lead to shortages of the antidote.

U.S. health care providers wrote more than 191 million prescriptions for opioids in 2017, according to the Centers for Disease Control and Prevention.

“Co-prescribing is the least-effective method we talked about in terms of actually providing product to the patient,” said Raeford Brown, a professor of anesthesiology at the University of Kentucky’s College of Medicine who chaired the two-day meeting.

More than 70,000 people died of drug overdoses in 2017, with 47,600 succumbing to opioids, according to the CDC. Both totals are records. The number of deaths caused by prescription narcotics leveled off from the previous year, but the number of deaths from overdoses of the opioid fentanyl continued to skyrocket.

TribLIVE commenting policy

You are solely responsible for your comments and by using you agree to our Terms of Service.

We moderate comments. Our goal is to provide substantive commentary for a general readership. By screening submissions, we provide a space where readers can share intelligent and informed commentary that enhances the quality of our news and information.

While most comments will be posted if they are on-topic and not abusive, moderating decisions are subjective. We will make them as carefully and consistently as we can. Because of the volume of reader comments, we cannot review individual moderation decisions with readers.

We value thoughtful comments representing a range of views that make their point quickly and politely. We make an effort to protect discussions from repeated comments either by the same reader or different readers

We follow the same standards for taste as the daily newspaper. A few things we won't tolerate: personal attacks, obscenity, vulgarity, profanity (including expletives and letters followed by dashes), commercial promotion, impersonations, incoherence, proselytizing and SHOUTING. Don't include URLs to Web sites.

We do not edit comments. They are either approved or deleted. We reserve the right to edit a comment that is quoted or excerpted in an article. In this case, we may fix spelling and punctuation.

We welcome strong opinions and criticism of our work, but we don't want comments to become bogged down with discussions of our policies and we will moderate accordingly.

We appreciate it when readers and people quoted in articles or blog posts point out errors of fact or emphasis and will investigate all assertions. But these suggestions should be sent via e-mail. To avoid distracting other readers, we won't publish comments that suggest a correction. Instead, corrections will be made in a blog post or in an article.